Denosumab-related osteonecrosis of the jaws
- نوع فایل : کتاب
- زبان : انگلیسی
- مؤلف : A. Kyrgidis & K. A. Toulis
- چاپ و سال / کشور: 2010
Description
The case of a cancer patient who developed ONJ without previous history of irradiation or bisphosphonate administration has been published [6]. In this patient, ONJ was reported to have healed completely following sequestration, 15 months after drug discontinuation [6]. Despite the fact that this is the only case published to date, additional evidence published in scientific meeting proceedings suggest that the condition of ONJ may not be solely associated to bisphosphonates [7, 8]. Results from two randomized clinical trials (RCTs; NCT00321464 [8], NCT00330759 [7]) of denosumab in cancer patients with bone metastases report that ONJ occurred infrequently [7, 8] (Table 1). Both studies have current or prior intravenous or oral bisphosphonate administration in their exclusion criteria [7, 8], thus bisphosphonates as an etiopathological factor for ONJ in those participants who received denosumab can be ruled out. Since ONJ has not been previously described to be associated with other drugs agents administered to cancer patients [2], it can be suggested that these cases of ONJ are related to denosumab administration.
Osteoporos Int (2011) 22:369–370 DOI 10.1007/s00198-010-1177-6 Received: 7 January 2010 / Accepted: 12 January 2010 / Published online: 20 March 2010
